It does not appear to engage the vagal and peripheral pathways that mediate the gastrointestinal punishment of GLP-1 agonism
www.ixpertadvisors.com #DCATWeek #Pharma #CDMO #Biotech #PharmaManufacturing #USPharma #iXPERTAdvisors To view or add a comment, sign in In 2026, pharmaceutical manufacturers could be caught between a cliff and a hard place
Movement and exercise stimulate intestinal contractions that propel stool forward, so 2030 minutes of daily activity (walking, swimming, cycling) can significantly improve regularity
Control glucmico en diabetes tipo 2 En estudios clnicos separados, la semaglutida oral a dosis de 14 mg diarios redujo la A1C en aproximadamente 1.0-1.4% desde el valor basal, mientras que la semaglutida inyectable a dosis de 1 mg semanal logr reducciones de 1.5-1.8%
UroLift : UroLift is a minimally invasive therapy for BPH where the enlarged prostate is not removed but held open with small implantable traction devices